Kyntra Bio, Inc. (KYNB) stock
KYNBNasdaqPharmaceutical PreparationsFiscal year ends December 31
$1.83−0.12 (-6.15%)
Close on Nov 19, 2026Market cap $7.41MP/E 0.0Yield –
Kyntra Bio free cash flow
Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.
Kyntra Bio's free cash flow for the twelve months ending Jun 30, 2026 was -$38.06M. For fiscal 2025 it was -$4.81M. The highest annual figure on record is $77.61M in fiscal 2020.
Annual free cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$4.81M | – |
| FY2024 | Dec 31, 2024 | -$138.27M | – |
| FY2023 | Dec 31, 2023 | -$317.54M | – |
| FY2022 | Dec 31, 2022 | -$149.67M | – |
| FY2021 | Dec 31, 2021 | -$87.42M | -212.6% |
| FY2020 | Dec 31, 2020 | $77.61M | – |
| FY2019 | Dec 31, 2019 | -$84.47M | – |
| FY2018 | Dec 31, 2018 | -$84.16M | – |
| FY2017 | Dec 31, 2017 | -$75.01M | -1381.0% |
| FY2016 | Dec 31, 2016 | $5.86M | – |
| FY2015 | Dec 31, 2015 | -$20.55M | -243.7% |
| FY2014 | Dec 31, 2014 | $14.30M | -25.2% |
| FY2013 | Dec 31, 2013 | $19.11M | – |
Quarterly free cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$3.99M | -131.5% |
| Q1 FY2026 | Mar 31, 2026 | -$13.89M | -613.8% |
| Q4 FY2025 | Dec 31, 2025 | -$18.33M | – |
| Q3 FY2025 | Sep 30, 2025 | -$1.86M | – |
| Q2 FY2025 | Jun 30, 2025 | $12.67M | – |
| Q1 FY2025 | Mar 31, 2025 | $2.70M | – |
| Q4 FY2024 | Dec 31, 2024 | -$30.61M | – |
| Q3 FY2024 | Sep 30, 2024 | -$8.46M | – |
| Q2 FY2024 | Jun 30, 2024 | -$39.88M | – |
| Q1 FY2024 | Mar 31, 2024 | -$59.32M | – |
| Q4 FY2023 | Dec 31, 2023 | -$18.57M | – |
| Q3 FY2023 | Sep 30, 2023 | -$85.22M | – |
| Q2 FY2023 | Jun 30, 2023 | -$111.56M | – |
| Q1 FY2023 | Mar 31, 2023 | -$102.18M | – |
| Q4 FY2022 | Dec 31, 2022 | -$52.85M | – |
| Q3 FY2022 | Sep 30, 2022 | -$52.75M | -223.6% |
| Q2 FY2022 | Jun 30, 2022 | -$33.97M | – |
| Q1 FY2022 | Mar 31, 2022 | -$10.11M | – |
| Q4 FY2021 | Dec 31, 2021 | -$56.36M | – |
| Q3 FY2021 | Sep 30, 2021 | $42.68M | – |
| Q2 FY2021 | Jun 30, 2021 | -$28.24M | -119.0% |
| Q1 FY2021 | Mar 31, 2021 | -$45.50M | – |
| Q4 FY2020 | Dec 31, 2020 | -$9.62M | – |
| Q3 FY2020 | Sep 30, 2020 | -$1.77M | – |
| Q2 FY2020 | Jun 30, 2020 | $148.94M | – |
| Q1 FY2020 | Mar 31, 2020 | -$59.95M | -372.5% |
| Q4 FY2019 | Dec 31, 2019 | -$46.80M | – |
| Q3 FY2019 | Sep 30, 2019 | -$29.29M | -512.5% |
| Q2 FY2019 | Jun 30, 2019 | -$30.38M | – |
| Q1 FY2019 | Mar 31, 2019 | $22.00M | – |
| Q4 FY2018 | Dec 31, 2018 | -$20.63M | – |
| Q3 FY2018 | Sep 30, 2018 | $7.10M | – |
| Q2 FY2018 | Jun 30, 2018 | -$36.83M | – |
| Q1 FY2018 | Mar 31, 2018 | -$33.80M | – |
| Q4 FY2017 | Dec 31, 2017 | -$4.69M | – |
| Q3 FY2017 | Sep 30, 2017 | -$21.81M | – |
| Q2 FY2017 | Jun 30, 2017 | -$20.73M | – |
| Q1 FY2017 | Mar 31, 2017 | -$27.77M | – |
| Q4 FY2016 | Dec 31, 2016 | -$18.69M | – |
| Q3 FY2016 | Sep 30, 2016 | -$1.85M | – |
See a number that looks wrong?